

Already Expired: Moderna’s upcoming Omicron shot is formulated for a variant that no longer exists

BA.1 is no longer spreading.

By [Jordan Schachtel](#)


Global Research, June 23, 2022

[The Dossier](#) 22 June 2022

Moderna’s reformulated mRNA COVID injection, the highly touted — and continuously delayed — “Omicron vaccine,” was tailored to an Omicron subvariant that no longer exists.

The pharmaceutical company’s Omicron-specific shot was formulated for the BA.1 subvariant of Omicron, which hasn’t been identified in genomic surveillance for several months.

Here’s the data directly from the [CDC’s genomic surveillance tracker](#):



As you can see, BA. 1 is now registering at 0%, and it has been superseded by several newer variants.



Yasmeeen Abutaleb @yabutaleb7

[Moderna is seeking approval for an omicron-specific booster that it hopes to distribute in the fall. The shot was tested against BA.1 and was more effective, but it's unclear how effective it'll be against current omicron strains.](#)



[Moderna seeking FDA authorization of omicron-specific booster shot Company says updated coronavirus vaccine produces more antibodies against omicron, but it's unclear how effective it might be against latest variants.washingtonpost.com](#)

June 8th 2022

2 Retweets 4 Likes

Moderna released a press release Wednesday touting its Omicron injection, but admitted that the “[shot elicited a weaker response versus BA.4 and BA.5,](#)” according to Reuters. Moreover, the shot has not even been tested on the latest subvariant, BA 2.12.1.

The Massachusetts-based biotech company drove tons of positive press for its preliminary findings that were released a [couple of weeks ago](#), ostensibly showing that the Omicron booster performed better than the original shot. However, those findings were solely performed on the sub variant that is no longer in circulation, rendering that data completely useless.

[\[Subscribe to my new Callin podcast. It's free!\]](#)

As for how many Omicron shots you should take in addition to your 4 to 5 older injections, Moderna hasn't yet nailed down “the science” on that either.

“It is probably long lasting and I think the conclusions are that boosting or primary vaccination with (the updated vaccine) really could be a turning point in our fight against SARS-cov-2 virus,” Moderna Chief Medical Officer Paul Burton [said](#) in a press conference Wednesday. You can't help but notice the overly cautious language from Moderna's CMO.

The Omicron shot has been in development for several months. For reasons unknown, both Pfizer and Moderna continue to delay expectations for its release. Moderna has settled on a

shot designed for the no longer existent BA.1 sub variant. Pfizer has yet to release preliminary findings on its own variant shot.



ABC 10News San Diego @10News

[Moderna and Pfizer tailor booster shots to fight omicron variant](#)



[Moderna and Pfizer tailor booster shots to fight omicron variant](#)
[If COVID-19 booster shots become an annual precaution, the same way we get a flu shot every year, the next one may be formulated differently.](#)
bit.ly

March 11th 2022

1 Retweet 1 Like

Meanwhile, Moderna and Pfizer continue to promote their original vaccines, which were developed in January of 2020 for the Wuhan strain, on infants and toddlers. There is already plenty of existing data that shows these shots do not provide any lasting immunity to the more current strains of the virus.



Prof. Dr. Sanjeev Bagai @BagaiDr

[Vaccines protect against infection from Omicron subvariant, but not for long. Qatar: 2vax of Pfizer or Moderna mRNA-hv mths of protection vs symptomatic dis by BA.1 or BA.2; protection ↓ to 10% after 4-6mth; vac prevented only 10% of cases that would have occur](#)



[Vaccines protect against infection from Omicron subvariant — but not for long](https://www.nature.com)
[Two doses of COVID vaccine cut the risk of infection and mild illness from the rising BA.2 subvariant, although protection wanes quickly.](https://www.nature.com)
[nature.com](https://www.nature.com)

March 20th 2022

2 Likes

Despite that, the government was happy to endorse America becoming the only country in the world to give mRNA injections to babies and toddlers.

Instead, the company has continued to churn out emergency use authorization shots, which again, are formulated for the no longer existent strain that was identified in late 2019 in Wuhan, China

Moderna is [projecting an estimated \\$15 billion](#) in profit this year, driven entirely by its only product on the market: an expired and worthless COVID shots, and a soon to come expired and worthless COVID shot. The original shots are sold to the government at about \$22 a piece, producing a [70% profit margin](#). Moreover, the government has funded virtually all of Moderna's research and development costs. Surely, the Omicron shot will cost taxpayers even more, much to the delight the several newfound billionaires who serve atop Moderna's c-suite.

The original source of this article is [The Dossier](#)
Copyright © [Jordan Schachtel](#), [The Dossier](#), 2022

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: **Jordan Schachtel**

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca